Business

Director appointment

Director appointment.

articleBrooks Macdonald Group PlcFebruary 16, 20234/company/brooks-macdonald-group/news/director-appointment-132
Director appointment

About this update from Brooks Macdonald Group Plc

[{"type":"text","content":"\n \n \n 16\n February 2023\n \n \n \n  \n \n \n \n \n BROOKS MACDONALD GROUP PLC\n \n \n \n \n  \n \n \n \n \n Director appointment\n \n \n \n \n  \n \n \n \n Brooks Macdonald Group plc (\"The Group\", \"Brooks Macdonald\") is pleased to announce the appointment of James Rawlingson as Non-Executive Director effective 2 March 2023. James will in due course assume the role of Chairman of the Audit Committee, subject to regulatory approval.\n \n \n  \n \n \n James currently serves as Chairman of the Audit and Risk Committee at Citibank UK, Chairman of the Audit and Risk Assurance Committee at the Foreign Office's executive agency Wilton Park, and Chairman of the Board at Novai Ltd. In his executive career James has held senior positions at Coutts, UBS Wealth, Charles Stanley plc and Arix Bioscience plc.\n \n \n  \n \n \n Commenting on the appointment, Acting Chairman Richard Price said: \"I am delighted that James is joining the Board. James has had an extensive career and his sector experience will provide valuable insight as the Company continues towards its strategic goals.\"\n \n \n  \n \n \n \n AIM disclosures\n \n \n \n \n  \n \n \n \n During the five years immediately preceding the date of this announcement, James Hedley Rawlingson, who is 55 years old, held the following directorships:\n \n \n  \n \n \n \n Current\n \n \n \n \n  \n \n \n \n Citibank UK Limited\n \n \n Wilton Park (an Arm's Length Body of the British Foreign, Commonwealth & Development Office)\n \n \n Novai Limited\n \n \n \n  \n \n \n \n \n Previous\n \n \n \n \n  \n \n \n \n Next Gen PPE limited\n \n \n Arix Bioscience Holdings Limited\n \n \n Arix Bioscience plc\n \n \n Arthurian Life Sciences GP Limited\n \n \n Als SPV Limited\n \n \n Arix Capital Management Limited\n \n \n Arthurian Life Sciences SPV GP Limited\n \n \n  \n \n \n There is no further information to be disclosed pursuant to Schedule Two Part (g) of the AIM Rules for Companies.\n \n \n  \n \n \n \n Enquiries to:\n \n \n \n Brooks Macdonald Group plc\n \n \n Andrew Shepherd, CEO\n \n \n www.brooksmacdonald.com\n \n \n 020 7927 4816\n \n \n  \n \n \n Peel Hunt LLP (Nominated Adviser and Broker)\n \n \n Paul Shackleton / Andrew Buchanan / John Welch\n \n \n 020 7418 8900\n \n \n  \n \n \n FTI Consulting\n \n \n Lau...

More updates from Brooks Macdonald Group Plc